Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 14/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.62 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.61 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.61 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.60 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.60 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.57 |
| ▸ | KRAS | P01116 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3083804 | 0.89 | PTGDR2 (0.68) | PTGDR2CYP2C9PTGDRAKR1B10AKR1B1 | |
| SCHEMBL14067844 | 0.89 | AKR1B10 (0.56) | PTGDR2CYP2C9PTGER2PTGDRAKR1B10 | |
| SCHEMBL3085456 | 0.88 | KRAS (0.67) | PTGDR2CYP2C9PTGDRAKR1B10AKR1B1 | |
| SCHEMBL3089604 | 0.88 | BAZ2B (0.74) | PTGDR2PTGER2PTGDRAKR1B10AKR1B1 | |
| SCHEMBL2086484 | 0.85 | PTGDR2 (0.72) | PTGDR2CYP2C9PTGER2PTGDRAKR1B10 | |
| SCHEMBL4719539 | 0.85 | PTGDR2 (0.58) | PTGDR2CYP2C9PTGER2PTGDRBAZ2B | |
| SCHEMBL5108079 | 0.84 | BAZ2B (0.53) | PTGDR2CYP2C9PTGER2PTGDRBAZ2B | |
| SCHEMBL4365131 | 0.83 | PTGDR2 (0.61) | PTGDR2CYP2C9PTGDRAKR1B10AKR1B1 | |
| SCHEMBL14067960 | 0.83 | AKR1B10 (0.50) | PTGDR2CYP2C9PTGER2PTGDRAKR1B10 | |
| SCHEMBL3084994 | 0.83 | PTGDR2 (0.68) | PTGDR2CYP2C9PTGER2PTGDRAKR1B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234396-A1 | Tetrhydropyridoindole Derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2010-09-16 | — | — | US | claimed |
| EP-1725553-B1 | TETRAHYDROPYRIDOINDOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-05-07 | — | — | EP | claimed |
| EP-1725553-A1 | TETRAHYDROPYRIDOINDOLE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2006-11-29 | — | — | EP | claimed |
| WO-2005095397-A1 | TETRAHYDROPYRIDOINDOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2005-10-13 | — | — | WO | claimed |
| US-20140328861-A1 | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis | ATOPIX THERAPEUTICS LTD (GB) | 2014-11-06 | — | — | US | disclosed |
| EP-2790696-A1 | COMBINATION OF CRTH2 ANTAGONIST AND A PROTON PUMP INHIBITOR FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS | Atopix Therapeutics Limited (GB) | 2014-10-22 | — | — | EP | disclosed |
| WO-2013088109-A1 | COMBINATION OF CRTH2 ANTAGONIST AND A PROTON PUMP INHIBITOR FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS | OXAGEN LIMITED (GB) | 2013-06-20 | — | — | WO | disclosed |
| US-20100234396-A1 | Tetrhydropyridoindole Derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2010-09-16 | — | — | US | disclosed |
| US-7714132-B2 | Tetrahydropyridoindole derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2010-05-11 | — | — | US | disclosed |
| EP-1725553-B1 | TETRAHYDROPYRIDOINDOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-05-07 | — | — | EP | disclosed |
| US-20070191416-A1 | Tetrahydropyridoindole derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2007-08-16 | — | — | US | disclosed |
| EP-1725553-A1 | TETRAHYDROPYRIDOINDOLE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005095397-A1 | TETRAHYDROPYRIDOINDOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234396-A1 | Tetrhydropyridoindole Derivatives | TPH2, TPH1, HTR5A | PTGDR2 170/4885CYP2C9 102/4885PTGER2 351/4885 |
| US-20070191416-A1 | Tetrahydropyridoindole derivatives | TPH2, TPH1, HTR2C | PTGDR2 154/4885CYP2C9 67/4885PTGER2 213/4885 |
| US-20140328861-A1 | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis | HRH2, HRH1, HRH4 | PTGDR2 59/4885CYP2C9 2737/4885PTGER2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.